Pediatr. praxi. 2010;11(2):121-124

Comparing of pharmacological, dietetic and regimen arrangements in hyperlipidemias treatment

MUDr.Jiří Hyjánek1, MUDr.Dalibor Pastucha, Ph.D.2
1 Ústav lékařské genetiky a fetální medicíny LF UP a FN Olomouc
2 Klinika rehabilitace a tělovýchovného lékařství LF UP a FN Olomouc

for atherosclerosis prevention in childhood

Hyperlipidemias are one of the commonest inherited metabolic disorders. They are a risk factor for atherosclerosis and cardiovascular

diseases. The article compares non-pharmacological and pharmacological treatment of these conditions in children and adolescents.

The results of atorvastatin treatment (10 mg daily) are compared with international randomised studies.

Keywords: hyperlipidemias, atherosclerosis, familial hypercholesterolemia, atorvastatin, children, treatment

Published: May 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hyjánek J, Pastucha D. Comparing of pharmacological, dietetic and regimen arrangements in hyperlipidemias treatment. Pediatr. praxi. 2010;11(2):121-124.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Šamánek M, Urbanová Z. Prevence aterosklerózy v dětském věku. Praha Galén 2003: 42-44.
    2. Curie C, Hurrelmann K, Settertobylte W, et al. Health and health behaviour among young people. Geneva: WHO, 2000.
    3. Šamánek M, Urbanová Z. Cholesterol and triglyceride levels and their development from 2 to 17 years of age. Cas Lek Cesk. 1997; 136(12): 380-385. Go to PubMed...
    4. Vrablík M, Češka R. Sekundární dyslipoproteinémie. Via Practica 2004; 1: 25-29.
    5. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholerolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003; 141: 74-80. Go to original source... Go to PubMed...
    6. Hubacek JA. Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants. Clin Chem Lab Med 2005; 43: 897-902. Go to original source... Go to PubMed...
    7. Urbanová Z, Šamánek M. Co nového je v diagnostice a léčbě dyslipidemií v dětství a dospívání. Vnitř Lék 2007; 53(12): 15.
    8. Stožický F. Hyperlipidemie u dětí. Pediatrie pro praxi 2002; 4: 176-171.
    9. Pastucha D, Horáková D, Janotová G, et al. Epidemiologie metabolického syndromu a možnosti prevence pohybovou aktivitou. Epidemiologie, mikrobiologie, imunologie 2007; 56(4): 181-185.
    10. National Cholesterol Education Programe. Report of the Expert Panel on Blood cholesterol Levels in Children and Adolescents. Pediatrics 1992; 89(Suppl): 525-528. Go to original source...
    11. Grundy SM, Cleeman JI, Merz CN, et al. Implications of Recent Clinical Trials for the National Cholesterol Education. Circulation 2004; 110: 227-239. Go to original source... Go to PubMed...
    12. Urbanová Z, Šamánek M, Češka R, et al. Doporučení pro diagnostiku a léčbu dyslipidemií u dětí a dospívajících, vypracované výborem České společnosti pro aterosklerózu. Cor Vasa 2008; 50(2): K41-K47.
    13. Muňoz T, Alonzo M, Oyarzabal M, et al. Safety and efficacy of atorvastatin vs. colestipol in children and adolescents with familial hypercholesterolemia. Circulation 2003; 108(17): IV 689.

    Return to the content


    Pediatrics for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.